Abstract: A radio network controller (RNC) receives a request to activate a packet data protocol (PDP) context for a wireless device operating in a forward access channel state. The RNC sends the request to activate PDP context to a core network node (CN). The RNC receives a request to assign a radio access bearer from the CN. The RNC sends a response to the request to assign a radio access bearer to the CN and initiates a timer. If the CN accepts the request to activate the PDP context prior to timer expiry, the RNC stops the timer and sends the wireless device the accept message followed by a request to reconfigure a radio bearer. Otherwise, if the timer expires, the RNC sends the wireless device the request to reconfigure the radio bearer followed by the accept message.

Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.

Abstract: A gas turbine engine installation is provided that has a plurality of flexible printed circuit board (FPCB) harnesses to transfer electrical signals, including electrical power, around a gas turbine engine. The plurality of FPCB harnesses is held to the gas turbine engine installation using clips that have at least two jaws. Each jaw has two sets of opposing teeth that do not intermesh, and cannot intermesh when pushed together. This allows more than one FPCB harness to be held by one clip without the risk of damaging the FPCB harnesses. Preventing the teeth from intermeshing also allows subsequent FPCB harnesses to be inserted into the clip without undue difficulty even after a first FPCB harness has already been inserted.

Abstract: A method for managing content is provided. The method may include, by a content management apparatus, receiving a content request, searching for content information associated with the request, and causing writing of missing content information to an alert file. The method may provide default content information when content information is not otherwise located. A content request may comprise an application and context name. A response from a content management apparatus may comprise a location and map identifier used by a calling apparatus to locate and cause display of content. The method may provide synchronization capabilities in which content referenced by an application is searched for in order to track missing content in an alerts file, and to track the synchronization history or status of an application in a synchronization log. Corresponding systems, apparatuses, and computer program products are also provided.

Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.

Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

Abstract: A method for guided patient charting is provided. The method may include, by a patient charting apparatus, receiving a context based on patient history, visit reason, age, gender, and/or policy, and identifying recommended workflows based on the context, an access control list, and/or a rule set. The recommended workflows may then be visually distinguished from that of the non-recommended workflows. Recommendations at the field-level may also be provided. Administration of workflow settings is provided. Corresponding apparatuses and computer program products are also provided.

Abstract: Compositions and methods are disclosed for generating immunoglobulin structural diversity in vitro, and in particular, for reducing biases in V region and J segment gene utilization, and for generating immunoglobulin V-D-J recombination events in a manner that does not require D-J recombination to precede V-DJ recombination. Selection of advantageous combinations of immunoglobulin gene elements, including introduction of artificial diversity (D) segment genes and optimization of recombination signal sequence (RSS) efficiency, are disclosed.

Abstract: High surface area energy chips that can be used to make high surface area electrodes and methods for making high surface area energy chips are described. The energy chips comprise a monolithic conductive material comprising an open network of pores having an average pore diameter between about 0.3 nm and 30 nm. The conductive material forms a thin chip having a thickness of about 300 microns or less, and the thickness across different portions of the chip varies by less than 10% of the thickness. The high surface area energy chips may be used as electrodes in a variety of energy storage devices and systems such as capacitors, electric double layer capacitors, batteries, and fuel cells.

Abstract: A mold for casting sol-gel wafers is provided. The mold may be formed of multiple low-friction layers, for example, layers made of polytetrafluoroethylene (e.g., Teflon™). The layers may alternate between solid layers and well layers, with a gel formulation placed in wells of each well layer. A force may be applied to the layers during the gelling process to produce a solid, but wet and porous gel in the shape of the wells of the mold. The gel may be further processed to produce sol-gel derived monoliths having desired surface characteristics.

Abstract: Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.

Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.

Abstract: A method for managing content is provided. The method may include, by a content management apparatus, receiving a content request, searching for content information associated with the request, and causing writing of missing content information to an alert file. The method may provide default content information when content information is not otherwise located. A content request may comprise an application and context name. A response from a content management apparatus may comprise a location and map identifier used by a calling apparatus to locate and cause display of content. The method may provide synchronization capabilities in which content referenced by an application is searched for in order to track missing content in an alerts file, and to track the synchronization history or status of an application in a synchronization log. Corresponding systems, apparatuses, and computer program products are also provided.

Abstract: An in vitro system for generating sequence, and thus structural, diversity in proteins is described. The system can be constructed using appropriately selected nucleic acid molecules that encode regions of a selected protein or proteins and recombination signal sequences (RSS). The selected protein(s) can be, for example, immunoglobulin (Ig) V, D, J and/or C regions, regions of a non-immunoglobulin (non-Ig) protein, or a combination of Ig regions and non-Ig regions. Assembly of such appropriately selected components and their introduction into suitable recombination-competent host cells allows for recombination between the RSS sequences and introduction of sequence and structural diversity into the protein(s).

Abstract: An offset cancellation scheme for sense amplification is described. The scheme consists of group of transistors which are selectively coupled to high and low voltage levels via multi-phase timing. This results in a voltage level on sensing nodes of interest which are a function of transistor mismatch. The resulting voltage levels act to compensates for the transistor mismatch, thereby improving the reliability of the sense amplifier in the presence of process non-idealities. The offset cancellation scheme is applicable to numerous types of sense amplifiers, amplifiers, and comparators.

Abstract: Nanoporous sol-gel derived monoliths and methods for making nanoporous sol-gel derived monoliths are provided. The methods enable fine control over pore size and pore size distribution, e.g., so that pore sizes can be predetermined and precisely tuned over a range from 0.3 nm to about 30 nm, or over a range from about 0.3 nm to about 10 nm. The monoliths may be derived from any suitable sol-gel, but in some instances they are derived from silica sol-gels. The sol-gel derived monoliths with finely tunable pore sizes and narrow pore size distributions may be used for a variety of applications, e.g., as substrates or templates for high surface area electrodes, as substrates for high surface area sensor, or as a component in a filtration apparatus.

Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.